Literature DB >> 20447660

Serum cystatin C is an easy to obtain biomarker for the onset of renal impairment in heart transplant recipients.

Daniela Kniepeiss1, Doris Wagner, Gerhard Wirnsberger, Regina E Roller, Andrä Wasler, Florian Iberer, Karl-Heinz Tscheliessnigg.   

Abstract

OBJECTIVE: With the increasing longevity of heart transplant recipients, the long-term effects of cyclosporine on renal function have become more evident. Highly sensitive, early, and effective monitoring of posttransplant renal function is still being researched. This study aimed to evaluate the prognostic value of cystatin C for patients after heart transplantation.
METHODS: Seventy-three long-term recipients of a heart transplant more than 5 years before the study start were included in the analysis with a follow-up of 4 years. Serum creatinine, renal glomerular filtration rate calculated by the Modification of Diet in Renal Disease formula, and serum cystatin C levels were collected, and risk factors for renal dysfunction were assessed. Statistical analysis was performed for all patients.
RESULTS: Univariate analysis showed a prognostic impact of antihypertensive medication and onset of diabetes (P < .001) on renal failure after transplantation. Multivariate analysis yielded cystatin C measured at the study start as a superior prognostic parameter for all time points (area under the receiver operating characteristic 12 months: 0.963; 24 months: 0.910; 48 months: 0.949) compared with the conventionally used creatinine levels.
CONCLUSIONS: Our results showed an enormous potential of serum cystatin C as an early prognostic and easy to obtain biomarker for renal dysfunction after heart transplantation. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447660     DOI: 10.1016/j.jtcvs.2010.03.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  End-stage kidney disease after pediatric nonrenal solid organ transplantation.

Authors:  Rebecca L Ruebner; Peter P Reese; Michelle R Denburg; Peter L Abt; Susan L Furth
Journal:  Pediatrics       Date:  2013-10-14       Impact factor: 7.124

Review 2.  Emergence of biomarkers in nephropharmacology.

Authors:  Enver Khan; Vecihi Batuman; Juan J L Lertora
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.